Adalimumab is a disease-modifying antirheumatic drug (DMARD) and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNF\u03b1). Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization’s List of Essential Medicines. It is available as a biosimilar medication. In 2020, it was the 205th most commonly prescribed medication in the United States, with more than 2 million prescriptions.<\/p>\n
Adalimumab, trade name\u00a0Exemptia, is a potent TNF-inhibitor and anti-inflammatory drug manufactured and promoted by Zydus Group in India. When people have Rheumatoid Arthritis or other inflammatory diseases, it causes over-secretion of TNF, a protein naturally produced in the body, causing inflammation and damage to the joints.\u00a0Adalimumab<\/strong>\u00a0works as anti-TNF, blocking over production of TNF and its harmful effects on the body. It helps to reduce inflammation and alleviate the symptoms of arthritis and other joint disorders.<\/p>\n If Adalimumab Injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n adalimumab is a tumor necrosis factor (TNF) blocker indicated for treatment of: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis or Pediatric Uveitis.<\/p>\n Approval Date:<\/strong>2002 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cAdalimumab Injection\u201d based on the information you provide.<\/p>\nHow can 1 go about obtaining Adalimumab Injection?<\/h3>\n
HUM IRA (adalimumab) Injection, Solution for Subcutaneous use Initial U.S. Approval: 2002<\/h5>\n
ADALIMUMAB Exemptia Solution for subcutaneous use 40 mg\/0.8 mL single-use pre-filled syringe 20 mg\/0.4 mL single-use pre-filled syringe<\/h5>\n
References<\/h4>\n
\n
Adalimumab Injection
\nfor subcutaneous use Initial U.S. Approval: 2002<\/h2>\nFacts about Adalimumab Injection<\/h4>\n
\nProprietary Name:<\/strong> On Request
\nActive Ingredient(s):<\/strong> Adalimumab Injection
\nDosage Forms And Strengths:<\/strong>
\nManufacturer:<\/strong>
\nMedicine Approved By: –<\/strong> European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:\u00a0<\/strong>Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n